DexCom Inc. (DXCM) Stock
NASDAQDXCM has an Alpha Score of 56 out of 100 (moderate), computed on Nov 3, 2026 from 3 of 4 sub-scores. 12 members of Congress disclosed 25 trades in DXCM since 2015: 8 purchases and 17 sales, most recently Tina Smith (sale, May 7, 2026). 6 of the hedge funds AlphaScala tracks reported DXCM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $109.83M. Company insiders reported 0 open-market buys and 13 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 29.6 and its net margin 20.1% (key statistics as of Oct 29, 2026).
What is DXCM's Alpha Score?
How it works →Alpha Score of 56 reflects moderate overall profile with moderate momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 3, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded DexCom Inc. (DXCM)?
Most recent: Tina Smith (sale, May 7, 2026); records start May 27, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Tina Smith D-MN · Senate | 2026-05-07 | sale | $100k – $250k |
| Tina Smith D-MN · Senate | 2026-04-29 | partial sale | $100k – $250k |
| John Boozman R-AR · Senate | 2026-01-26 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-05-15 | purchase | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-05-12 | sale | $15k – $50k |
| Jefferson Shreve R-IN · House | 2025-05-08 | purchase | $15k – $50k |
| Rob Bresnahan R-PA · House | 2025-04-08 | sale | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-04-07 | sale | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded DXCM, with filing lags →Which hedge funds own DXCM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 1.63M | $109.83M | +3% |
| Citadel Ken Griffin | 1.21M | $81.61M | -42% |
| Marshall Wace | 533K | $35.88M | +681% |
| Bridgewater Associates Ray Dalio | 401K | $27.00M | +187% |
| Millennium Management Israel Englander | 395K | $26.63M | -76% |
| Point72 Steve Cohen | 283K | $19.05M | +10% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are DexCom Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 27, 26 | Stern Sadie | EVP Chief People & Culture Off | SELL | 2.6K | $202K |
| Oct 15, 26 | Brown Michael Jon | EVP Chief Legal Compliance Off | SELL | 1.7K | $145K |
| Sep 28, 26 | Stern Sadie | EVP Chief People & Culture Off | SELL | 2.6K | $221K |
| Sep 15, 26 | Brown Michael Jon | EVP Chief Legal Compliance Off | SELL | 1.7K | $143K |
| Sep 15, 26 | Augustinos Nicholas | Director | SELL | 6.5K | $550K |
| Sep 14, 26 | Augustinos Nicholas | Director | SELL | 1.6K | $130K |
| Sep 10, 26 | Sylvain Jereme M | EVP, Chief Financal Officer | SELL | 3.6K | $303K |
| Aug 27, 26 | Stern Sadie | EVP Chief People & Culture Off | SELL | 2.6K | $227K |
| Aug 20, 26 | Sayer Kevin R | Executive Chair | SELL | 19.3K | $1.7M |
| Aug 20, 26 | Sayer Kevin R | Executive Chair | SELL | 7.4K | $667K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are DXCM's key statistics?
Key statistics as of Oct 29, 2026
How does DXCM's valuation compare with the Healthcare sector?
| Metric | DXCM | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 29.6 | 28.8 | 111 |
| Net margin | 20.12% | 4.31% | 164 |
| Return on equity | 36.19% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
DXCM price chart
Powered by TradingViewWhat does DexCom Inc. do?
Dexcom Inc. is a medical device company specializing in the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes management and metabolic health in the United States and internationally. Its CGM systems provide real-time glucose data as an alternative to traditional finger-stick blood glucose testing, enabling better diabetes control for patients and healthcare providers. Key products include the Dexcom G6, an integrated CGM system; Dexcom G7, a next-generation sensor offering 15-day wear time and seamless integration; Dexcom ONE for simplified testing replacement; Dexcom Share for remote monitoring; and Dexcom Real-Time API for third-party app and device integrations. Dexcom Inc. also supports automated insulin delivery through compatibility with insulin pumps from partners like Insulet and Tandem. The company markets directly to endocrinologists, physicians, and diabetes educators, serving people with diabetes across type 1, type 2, and related conditions. Founded in 1999 and headquartered in San Diego, California, Dexcom Inc. plays a pivotal role in advancing real-time glucose monitoring technology within the healthcare sector.